CTX-471

DRUG3 trials

Sponsors

Compass Therapeutics, Washington University School of Medicine

Conditions

GlioblastomaHead and Neck CancerLocally Advanced Solid TumorMelanomaMesotheliomaMetastatic CancerNeuroendocrine CarcinomasNeuroendocrine Neoplasm

Phase 1

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

CompletedNCT03881488

Compass TherapeuticsHead and Neck Cancer, Locally Advanced Solid Tumor, Melanoma +4

Start: 2019-05-17End: 2025-05-21Updated: 2026-04-17

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

RecruitingNCT07392957

Washington University School of MedicineGlioblastoma

Start: 2026-06-16End: 2031-06-30Target: 54Updated: 2026-06-22

Phase 2

Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms

Not yet recruitingNCT07684170

Compass TherapeuticsNeuroendocrine Carcinomas, Neuroendocrine Neoplasm, Neuroendocrine Tumors

Start: 2026-09-01End: 2029-09-01Target: 58Updated: 2026-07-06

Related Papers

Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.

Journal of Clinical Oncology2024-06-011 citations